Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Sarepta Therapeutics (SRPT)

Sarepta reports Q3 GAAP net loss of $179.9 million on revenue of $399.4 million

Negative Impact 4 of 5 earnings Written later

Sarepta reported third-quarter 2025 total revenues of $399.4 million, down 15% from $467.2 million a year earlier, and a GAAP net loss of $179.9 million, or $1.80 per diluted share, compared with GAAP net income of $33.6 million a year earlier. The filing also disclosed that the ESSENCE confirmatory trial for AMONDYS 45 and VYONDYS 53 did not reach statistical significance on its primary endpoint, and the company plans to meet with the FDA about a path to traditional approval.

Key points

  • Total revenues were $399.4 million versus $467.2 million a year earlier; ELEVIDYS net product revenue fell $49.5 million after shipments to non-ambulatory patients in the U.S. were suspended in June 2025.
  • GAAP diluted loss per share was $1.80, compared with earnings of $0.34; non-GAAP diluted loss per share was $0.13, compared with earnings of $0.64.
  • A $138.6 million loss on debt extinguishment and $40.5 million in restructuring charges were recorded in the quarter.
  • Cash, cash equivalents, restricted cash and investments were $865.2 million at September 30, 2025, down from $1,503.5 million at December 31, 2024.

The filing

CompanySarepta Therapeutics (SRPT)
Form8-K, current report
Filed with the SECNov 3, 2025, 4:18 PM ET
Accession number0001193125-25-262591

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:55 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 03, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.